Anxiety Disorders Completed Phase 3 Trials for Duloxetine (DB00476)

Also known as: Anxiety Disorder / Anxiety NOS

IndicationStatusPhase
DBCOND0027904 (Anxiety Disorders)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00122850A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety DisorderTreatment
NCT00122863Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety DisorderTreatment
NCT00122824Duloxetine Compared With Placebo in Patients With Generalized Anxiety DisorderTreatment
NCT00114127Duloxetine for Social Anxiety Disorder: Prediction of Long Term OutcomeTreatment
NCT00122837A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety DisorderTreatment